[HTML][HTML] Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic …
Journal of Clinical Oncology, 2012•ncbi.nlm.nih.gov
Purpose A randomized, placebo-controlled study based on preclinical and clinical data that
supports the potential role of vascular endothelial growth factor in prostate cancer was
performed to evaluate the addition of bevacizumab to standard docetaxel and prednisone
therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
supports the potential role of vascular endothelial growth factor in prostate cancer was
performed to evaluate the addition of bevacizumab to standard docetaxel and prednisone
therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
Abstract
Purpose
A randomized, placebo-controlled study based on preclinical and clinical data that supports the potential role of vascular endothelial growth factor in prostate cancer was performed to evaluate the addition of bevacizumab to standard docetaxel and prednisone therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
ncbi.nlm.nih.gov
